FDA APPROVES AZILECT FOR PARKINSON'S TREATMENT

Teva Pharmaceutical Industries announced the FDA has approved Azilect to treat Parkinson's disease in both the early and advanced stages.

Azilect (rasagiline tablets) is the only once-a-day treatment for Parkinson's and one of the few indicated as monotherapy in the early stages and as an adjunct to levodopa in the more advanced stages, according to the company. It has just begun a new clinical study to determine if the drug also slows progress of the disease.